Clearmind Medicine (CMND)
Search documents
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
Newsfilter· 2024-02-05 12:51
Tel Aviv, Israel / Vancouver, Canada, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ((Nasdaq, CSE:CMND), (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has been granted divisional patent approval by the China National Intellectual Property Administration. The granting of this latest patent establishes both the company's patent protecti ...
Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
Newsfilter· 2024-02-01 13:15
The licensing agreement refers to the company's dedicated treatment for cocaine addiction which previously indicated a significant decrease in cocaine craving Tel Aviv, Israel / Vancouver, Canada, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ((Nasdaq, CSE:CMND), (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the signing of an exclusive long- ...
Clearmind Medicine (CMND) - 2023 Q4 - Annual Report
2024-01-28 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of eve ...
Clearmind Medicine (CMND) - 2023 Q3 - Quarterly Report
2023-09-12 16:00
(iii) On February 14, 2022, the Company completed a share purchase agreement with Medigus, whereby the Company issued a total of 66,244 units to Medigus in consideration for US$750,000 ("Cash Financing") and 27,778 common shares of Medigus ("Share Exchange"). Each unit is comprised of one common share and one warrant, with each warrant exercisable for a period of 18 months at CAD$60.00 per share. In addition, Medigus will be entitled to 10% of the initial equity of a potential venture in the area of psyched ...
Clearmind Medicine (CMND) - 2023 Q2 - Quarterly Report
2023-06-13 16:00
CLEARMIND MEDICINE INC. (Unaudited) Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) Alan Rootenberg, Director, CFO Adi Zuloff-Shani, Director, CEO F-2 Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Expressed in United States Dollars) (Unaudited) On November 14, 2022, the Company completed a public offering for aggregate gross proceeds of US$7.5 million and up listing to the Nasdaq Capital Market ("Nasdaq"), see ...
Clearmind Medicine (CMND) - 2023 Q1 - Quarterly Report
2023-03-16 16:00
c. Significant Accounting Estimates and Judgments (continued) Significant Judgments 3. Short-term Investment CLEARMIND MEDICINE INC. Notes to the Condensed Interim Consolidated Financial Statements (Expressed in Canadian Dollars) (Unaudited) a. Compensation to key management personnel | --- | --- | --- | |---------------------------------|-------|-------| | | | | | Amounts owed to officers | | | | | | | | Amounts owed to directors | | | CLEARMIND MEDICINE INC. (iii) During the three months ended January 31, ...
Clearmind Medicine (CMND) - 2022 Q4 - Annual Report
2023-02-05 16:00
Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Emerging Growth Company ☒ If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐ †The term "new or revised financial accounting standard" refers to any update issued by ...